Sites advertising it are offering an unapproved research chemical of unverified quality, which carries real safety and legal risks
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) - Full Text View - ClinicalTrials.gov (n.d.)
Alyssa Dominguez, an endocrinologist at the University of Southern Californias Keck School of Medicine, told Rolling Stone that the doses are super off compared to anything that was in research studies, like they were giving people 8,000 times the dose of what is in the patch. Dr
This latter pathway may have potent metabolic effects, even when endogenous GLP-1 blood concentrations are lower than pharmacologic GLP-1 levels [260]
FDA regulatory status - compounded GLP-1s: FDA proposed April 30, 2026 to exclude semaglutide and tirzepatide from 503B Bulks List
Using lower doses with comprehensive support actually reduces risk